Subscribe
shutterstock_787873258_-josefkubes
josefkubes / Shutterstock.com
18 July 2019Big PharmaSaman Javed

Johnson & Johnson braces for Q3 sales dip as generics bite

Johnson & Johnson (J&J) has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
J&J unit accuses rival of ‘shocking’ trade secrets theft
11 February 2021   A Johnson & Johnson unit has accused eye care product manufacturer Alcon of trade secrets theft, alleging that it had perpetrated “piracy of a nearly unfathomable scale” in ripping off a computer code.
Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
Americas
J&J reveals plans to appeal cancer drug court ruling
29 October 2018   Johnson & Johnson has revealed its intention to appeal against a district court’s invalidation of a patent covering its prostate cancer drug Zytiga (abiraterone acetate).


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
J&J unit accuses rival of ‘shocking’ trade secrets theft
11 February 2021   A Johnson & Johnson unit has accused eye care product manufacturer Alcon of trade secrets theft, alleging that it had perpetrated “piracy of a nearly unfathomable scale” in ripping off a computer code.
Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
Americas
J&J reveals plans to appeal cancer drug court ruling
29 October 2018   Johnson & Johnson has revealed its intention to appeal against a district court’s invalidation of a patent covering its prostate cancer drug Zytiga (abiraterone acetate).

More on this story

Americas
J&J unit accuses rival of ‘shocking’ trade secrets theft
11 February 2021   A Johnson & Johnson unit has accused eye care product manufacturer Alcon of trade secrets theft, alleging that it had perpetrated “piracy of a nearly unfathomable scale” in ripping off a computer code.
Americas
J&J to buy surgical robotics company for $3.4bn
18 February 2019   Johnson & Johnson has announced plans to strengthen its robotics programme with the addition of Silicon Valley-based Auris Health to its business.
Americas
J&J reveals plans to appeal cancer drug court ruling
29 October 2018   Johnson & Johnson has revealed its intention to appeal against a district court’s invalidation of a patent covering its prostate cancer drug Zytiga (abiraterone acetate).

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims